Stableford Capital II LLC Sells 6,964 Shares of Establishment Labs Holdings Inc. $ESTA

Stableford Capital II LLC lessened its holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 31.1% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 15,395 shares of the company’s stock after selling 6,964 shares during the period. Stableford Capital II LLC owned 0.05% of Establishment Labs worth $1,321,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Goldman Sachs Group Inc. raised its position in shares of Establishment Labs by 117.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock valued at $59,145,000 after buying an additional 438,206 shares during the last quarter. Viking Global Investors LP bought a new position in shares of Establishment Labs during the second quarter worth $14,669,000. Soleus Capital Management L.P. purchased a new position in Establishment Labs during the second quarter valued at $9,050,000. Summit Partners Public Asset Management LLC grew its stake in Establishment Labs by 87.1% during the third quarter. Summit Partners Public Asset Management LLC now owns 430,160 shares of the company’s stock valued at $17,632,000 after acquiring an additional 200,255 shares in the last quarter. Finally, Nantahala Capital Management LLC increased its holdings in Establishment Labs by 11.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company’s stock valued at $80,893,000 after acquiring an additional 197,962 shares during the last quarter. 72.91% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ESTA has been the topic of a number of research analyst reports. Citigroup boosted their target price on Establishment Labs from $76.00 to $92.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. TD Cowen raised their price target on Establishment Labs from $95.00 to $117.00 and gave the company a “buy” rating in a report on Monday. BTIG Research reaffirmed a “buy” rating on shares of Establishment Labs in a research note on Monday, July 13th. Mizuho increased their target price on Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research report on Wednesday, June 24th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $93.75.

Insider Buying and Selling

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total value of $7,919,100.00. Following the sale, the director owned 927,504 shares in the company, valued at $69,952,351.68. This trade represents a 10.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 9.99% of the stock is owned by company insiders.

Establishment Labs Stock Up 0.3%

Shares of NASDAQ ESTA opened at $92.80 on Tuesday. Establishment Labs Holdings Inc. has a 1 year low of $33.35 and a 1 year high of $97.59. The firm has a 50-day simple moving average of $85.34 and a two-hundred day simple moving average of $73.77. The company has a market cap of $2.73 billion, a P/E ratio of -62.28 and a beta of 1.07. The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The business had revenue of $59.88 million for the quarter, compared to the consensus estimate of $57.40 million. During the same period in the prior year, the company posted ($0.70) EPS. The company’s quarterly revenue was up 44.7% compared to the same quarter last year. Research analysts anticipate that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current year.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.